Aadi BioscienceAADI
AADI
Ticker changed
AADI changed its ticker symbol to WHWK
About: Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Employees: 53
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.
Neutral
PRNewsWire
3 weeks ago
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
MORRISTOWN, N.J. , March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025.
Positive
Zacks Investment Research
1 month ago
Aadi Bioscience, Inc. (AADI) Expected to Beat Earnings Estimates: Should You Buy?
Aadi Bioscience (AADI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
1 month ago
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
MORRISTOWN, N.J. , March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement.
Neutral
PRNewsWire
1 month ago
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
MORRISTOWN, N.J. , March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy
Aadi Bioscience (AADI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
1 month ago
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
MORRISTOWN, N.J. , Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA.
Neutral
PRNewsWire
1 month ago
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J. , Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO).
Neutral
PRNewsWire
2 months ago
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio Aadi's Board Recommends Stockholders Vote "FOR" All Proposals to Support the Company's Business Transformation Company Expects to Close Transactions in the First Quarter of 2025, Subject to Stockholder Approval and Other Closing Conditions MORRISTOWN, N.J. , Feb. 5, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on January 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") which is scheduled to be held on February 28, 2025.
Positive
Benzinga
3 months ago
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.
Charts implemented using Lightweight Charts™